ITC Staff Sides With Merck In NuvaRing Patent Battle

Law360, New York (January 11, 2012, 9:12 PM EST) -- The investigative staff of the U.S. International Trade Commission recommended in a prehearing brief made public Tuesday that evidence would likely show Merck & Co. Inc. did not violate a Femina Pharma Inc. patent covering birth control devices in marketing its NuvaRing product.

At issue is the U.S. Patent Number 6,086,909, issued in 2000 and titled "Device and method for treatment of dysmenorrhea," the brief said.

The '909 patent describes and claims a medicated intravaginal device, such as a vaginal ring, for transvaginal delivery of a...
To view the full article, register now.